By API User
Highlights U.S. clinical trials commenced with first patients enrolled over 8 recruitment centres Trial will validate the use of CLEO’s ovarian cancer blood test for the U.S. market Pathway set toward FDA submission in CY2025. ___________ MELBOURNE, AUSTRALIA, 6 September 2024: Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to … Continued
By API User
TEWKSBURY, MA / ACCESSWIRE / September 5, 2024 / Cambridge Isotope Laboratories, Inc. (CIL), the global leader in 13Cand 13C urea production, is excited to announce the startup of its North Star project, significantly increasing the company’s production capabilities. CIS AerialCIS Aerial The North Star project commenced in mid-2020 as the world’s largest 13C production … Continued
By API User
LUXEMBOURG / ACCESSWIRE / September 5, 2024 / Moolec Science SA (NASDAQ:MLEC) ("The Company", "Moolec"), a science-based food ingredient company, announced today the harvest confirmation of US campaigns for genetically engineered plant-grown products GLASO™ and Piggy Sooy™ during October 2024. GLASO™ and Piggy Sooy™ US Harvest Announcement GLASO™ (gamma-linolenic acid -GLA- in safflower oil) campaign … Continued
By API User
[Melbourne, Victoria, Australia]: Venture studio Blue Ocean Ventures today announced that it will continue supporting its first development project, SHRMP.bio, a biotech startup that aims to revolutionise seafood manufacturing using modern technology. The startup has made significant progress since its launch in February 2024 and has garnered attention by participating in Australian incubator programs run by … Continued
By API User
REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for the potential treatment of symptomatic CCM in subsequent studies. SALT LAKE CITY, Sept. 03, 2024 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to … Continued
By API User
Dr. Scholl is a globally recognized leader in the field of ophthalmology and the coordinating principal investigator of the largest ever natural history study of Stargardt disease SAN DIEGO, Sept. 01, 2024 (GLOBE NEWSWIRE) — Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel … Continued
By API User
*Audio grabs and images here* GPs could soon be able to screen their patients for Alzheimer’s Disease (AD) using a simple handheld device developed by Monash engineers. Monash engineers have developed the first-of-a-kind finger-prick blood test with ‘needle-in-a hay-stack’ precision to detect the hallmark (protein) biomarkers in early AD before symptoms progress. The size of a … Continued
By API User
With a grand vision of investing $66 million over 10 years in groundbreaking medical innovations, WEHI’s first strategic investment fund, 66ten, is the largest internal pre-seed and seed fund created by an Australian medical research institute. Managed by WEHI Ventures, 66ten serves the sole purpose of bridging the gap between scientific discoveries and commercial … Continued
By API User
Sydney, Australia – 21 August 2024 | Bioxyne Limited (ASX: BXN) (“Bioxyne” or “the Company”) is proud to announce that its 100% owned subsidiary, Breathe Life Sciences (BLS), has successfully manufactured and delivered Australia’s first pharmaceutical-grade cannabis pastilles (“Gummies” or “Edibles“) under its Good Manufacturing Practice (GMP) certification from the Therapeutic Goods Administration (TGA). This … Continued
By API User
Researchers have uncovered new clues about a mysterious immune-modulating protein with the ability to resolve inflammation in a variety of diseases including inflammatory bowel diseases, rheumatoid arthritis and those at risk of heart attack. In the preclinical study, published in the prestigious British Journal of Pharmacology, the Monash University team have described significant new insights into … Continued
